Last reviewed · How we verify
Granexin® gel 100 μM — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Granexin® gel 100 μM (Granexin® gel 100 μM) — Xequel Bio, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Granexin® gel 100 μM TARGET | Granexin® gel 100 μM | Xequel Bio, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Granexin® gel 100 μM CI watch — RSS
- Granexin® gel 100 μM CI watch — Atom
- Granexin® gel 100 μM CI watch — JSON
- Granexin® gel 100 μM alone — RSS
Cite this brief
Drug Landscape (2026). Granexin® gel 100 μM — Competitive Intelligence Brief. https://druglandscape.com/ci/granexin-gel-100-m. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab